MP17-09 EXPRESSION OF MONOACYLGLYCERASE (MAGL) IN THE HUMAN LOWER URINARY TRACT: A NEW TARGET FOR INTERVENTION INTO THE ENDOCANNABINOID SYSTEM ?

Abstract

You have accessJournal of UrologyBladder & Urethra: Anatomy, Physiology & Pharmacology1 Apr 2014MP17-09 EXPRESSION OF MONOACYLGLYCERASE (MAGL) IN THE HUMAN LOWER URINARY TRACT: A NEW TARGET FOR INTERVENTION INTO THE ENDOCANNABINOID SYSTEM ? Andrea Schreiber, Frank Strittmatter, Beata Rutz, Raphaela Waidelich, Martin Hennenberg, Christian G. Stief, and Christian Gratzke Andrea SchreiberAndrea Schreiber More articles by this author , Frank StrittmatterFrank Strittmatter More articles by this author , Beata RutzBeata Rutz More articles by this author , Raphaela WaidelichRaphaela Waidelich More articles by this author , Martin HennenbergMartin Hennenberg More articles by this author , Christian G. StiefChristian G. Stief More articles by this author , and Christian GratzkeChristian Gratzke More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.530AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Endocannabinoids (2-arachidonoylglycerol, 2-AG, and anandamide) play an important role in the control of smooth muscle tone in the lower urinary tract, and of micturition. Recent studies suggested that the endocannbinoid system may be an attractive target for therapy of lower urinary tract symptoms (LUTS). Inhibition of anandamide degradation by inbitors of FAAH causes beneficial urodynamic effects in rats with experimental urethral obstruction. However, expression of monoacylglycerase (MAGL), which degrades 2-AG, has not been addressed in the lower urinary tract. Objective: To examine the expression of MAGL in the human bladder and prostate. METHODS Prostate tissues were obtained from patients undergoing radical prostatectomy. Detrusor tissues were obtained from the trigonum of bladders from radical cystectomy. Expression of MAGL was investigated by Western blot analysis. Localization was examined by double fluorescence staining. RESULTS MAGL and FAAH were detected by Western blot analyses in the human prostate and trigonum. In the prostate, MAGL colocalized with calponin and pan-cytokeratin, indicating expression in smooth muscle cells and in the glandular epithelium. In smooth muscle cells of the prostate, MAGL colocalized with FAAH. In the trigonum, double labelling with calponin indicated expression of MAGL and FAAH in smooth muscle cells. However, MAGL and FAAH showed no colocalization in the trigonum, indicating expression in separate smooth muscle cells. In addition, immunoreactivity for MAGL was observed in the urothelium, being even stronger as immunoreactivity in the smooth muscle. Expression of cannabinoid receptor 1 and 2 (CB1, CB2) was observed in smooth muscle cells of the trigonum, where immunoreactivity colocalized with MAGL. CONCLUSIONS MAGL is expressed in the human detrusor and prostate, where it may be critical for endocannabinoid availability. While MAGL is coexpressed with FAAH in smooth muscle cells of the prostate, smooth muscle cells in the detrusor express either MAGL, or FAAH. Inclusion of MAGL into cannabinoid-based therapies may enhance urodynamic effects in experimental models or clinical studies. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e138 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Andrea Schreiber More articles by this author Frank Strittmatter More articles by this author Beata Rutz More articles by this author Raphaela Waidelich More articles by this author Martin Hennenberg More articles by this author Christian G. Stief More articles by this author Christian Gratzke More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...